8 July 2020 

GlaxoSmithKline (GSK) has partnered with Canadian biopharmaceutical firm Medicago to develop, assess and manufacture a plant-based adjuvanted Covid-19 vaccine candidate. As part of the collaboration, GSK’s pandemic adjuvant system will be combined with Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP). The companies expect to complete development and make the vaccine available in the first half of next year.

Regeneron Pharmaceuticals has received a $450m contract from the US Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense to manufacture and supply its antibody cocktail, REGN-COV2, designed to act against Covid-19. The company has already started scaling up the therapy’s production and this contract is intended to enable continued manufacturing.

Corvus Pharmaceuticals has launched a Phase I clinical trial to assess a new immunotherapy, which is designed as an agonistic humanised monoclonal antibody, for the treatment of Covid-19 patients. The first cohort of five participants in the trial was treated at Temple University Hospital in Philadelphia. A total of up to 30 patients will be enrolled at various sites in the US.

7 Hills Pharma has reported that its oral immunostimulant candidate, 7HP349, significantly increased IgG binding antibodies with a Covid-19 vaccine candidate in preclinical studies. The company added that 7HP349 enhances a vaccine’s effectiveness, as well as accelerates immune system response. The immunostimulant can be used with any Covid-19 vaccine, added 7 Hills Pharma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.